Investor Presentaiton

Neuroscience Anti-MTBR-Tau elF2B Activator Phase 1 data supports rapidly moving BMS-986446 into Phase 2 Phase 1 Findings1 8 Safe and well-tolerated in Phase 1 across 3 dose cohorts; no deaths or SAEs observed in healthy participants Demonstrated dose-proportional anti-tau concentrations in plasma with CNS penetration in healthy participants Q No persistent anti-tau-induced anti-drug antibodies observed ㅁㅁㅁ Robust exposure in the CSF at 1-month predicts substantial target engagement in CNS R 1:1:1 PoC in Alzheimer's Disease to initiate in 1H 2024 Double-blind treatment period Placebo BMS-986446 Dose 1 BMS-986446 Dose 2 Optional long-term extension and follow-up Ill Bristol Myers Squibb 1. Martenyi, et al AAIC 2023 Poster 74181 Not for Product Promotional Use 129

View entire presentation